The search for new COX-2 inhibitors: a review of 2002 – 2008 patents

Bibliography

• Pillai AD, Rathod PD, Xavier FP, et al. Tetra substituted thiophenes as anti-inflammatory agents: exploitation of analogue-based drug design. Bioorg Med Chem 2005;13(24):6685-92
   PubMed Web of Science ®Google Scholar
• Wilson LM. In: Price SA, Wilson LM, editors, Pathophysiology: clinical concepts of disease processes, Mosby St. Louis, Missouri. 2003. p. 44-61
   Google Scholar
• Cicconetti A, Bartoli MDA, Ripari FDDS, Ripari A. Cox-2 selective inhibitors: a literature review of analgesic efficacy and safety in oral-maxillofacial surgery. Oral Srug Med Oral Pathol 2004;97(2):139-46
   Google Scholar
• Radi ZA, Khan NK. Effects of cyclooxygenase inhibition on the gastrointestinal tract. Exp Toxicol Pathol 2006;58:163-73
   PubMed Web of Science ®Google Scholar
• Kiefer JR, Pawlitz JL, Moreland KT, et al. Structural insights into the stereochemistry of the cyclooxygenase reaction. Nature 2000;405(6782):97-101
   Google Scholar
• Capone ML, Tacconelli S, Di Francesco L, et al. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat 2007;82 Special Issue:85-94
   PubMed Web of Science ®Google Scholar
• Patrignani P, Tacconelli S, Sciulli MG, Capone ML. New insights into COX-2 biology and inhibition. Brain Res Rev 2005;48:352-9
   PubMedGoogle Scholar
• GD Searle & Co. Substituted pyrazolyl benzenesulfonamides. US5466823; 1993
   Google Scholar
• Merck Frosst Canada & Co. Phenyl heterocycles as cyclooxygenase-2 inhibitors. WO09500501; 1995
   Google Scholar
• Penning TD, Talley JJ, Bertenshaw SR, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). J Med Chem 1997;40(9):1347-65
   PubMed Web of Science ®Google Scholar
• Chan CC, Boyce C, Brideau C, Charleson S, et al. Rofecoxib [Vioxx, MK-0966; 4-(49-Methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 1999;290:551-60
   PubMed Web of Science ®Google Scholar
• Available from: http.://www.vioxx.com.
   Google Scholar
• Talley J, Brown DL, Nagarajan S, Carter JS, et al. Substituted isoxazoles for the treatment of inflammation. US5633272; 1997
   Google Scholar
• Fricke J, Varkalis J, Zwillich SAM, et al. Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery. J Ther 2002;9(2):89-97
   Google Scholar
• Jain KK. Evaluation of intravenous parecoxib for the relief of acute post-surgical pain. Expert Opin Invest Drugs 2000;9(11):2717-23
   PubMed Web of Science ®Google Scholar
• Cochrane DJ, Jarvis B, Keating GM. Etoricoxib. Drugs 2002;62(18):2637-51
   PubMed Web of Science ®Google Scholar
• Bannwarth B, Bérenbaum F. Lumiracoxib in the management of osteoarthritis and acute pain. Expert Opin Pharmacother 2007;8:1551-64
   PubMed Web of Science ®Google Scholar
• Karnik PS, Johnston S, Ward D, et al. The effects of epidural deracoxib on the ground reaction forces in an acute stifle synovitis model. Vet Surg 2006;35:34-42
   Google Scholar
• Tacconelli S, Capone ML, Patrignani P. Clinical pharmacology of novel selective COX-2 inhibitors. Curr Pharm Des 2004;10:589-601
   PubMed Web of Science ®Google Scholar
• Rahme E, Nedjar H. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rheumatology 2007;46:435-8
   PubMed Web of Science ®Google Scholar
• Warner TD, Mitchell JA. COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet 2008;371:270-3
   PubMed Web of Science ®Google Scholar
• Kulmacz RJ, Wang LH. Comparison of hydroperoxide initiator requirements for the cyclooxygenase activities of prostaglandin H synthase-1 and -2. J Biol Chem 1995;270:24019-23
   PubMed Web of Science ®Google Scholar
• Ueno N, Murakami M, Tanioka T, et al. Coupling between cyclooxygenase, terminal prostanoid synthase, and phospholipase A2. J Biol Chem 2001;276:34918-27
   PubMed Web of Science ®Google Scholar
• Dajani EZ, Islam K. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man. J Physiol Pharmacol 2008;59(Suppl 2):117-33
   PubMedGoogle Scholar
• Huntjens DR, Danhof M, Della Pasqua OE. Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology (Oxford) 2005;44:846-59
   PubMed Web of Science ®Google Scholar
• Solomon SD, Mcmurray JJ, Pfeffer MA. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80
   PubMed Web of Science ®Google Scholar
• Andersohn F, Suissa S, Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 2006;113:1950-7
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Gonzalez-Perez A. Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC Med 2005;3:17-21
   PubMed Web of Science ®Google Scholar
• Marnett LJ, Rowlinson SW, Goodwin DC, et al. Arachidonic acid oxygenation by COX-1 and COX-2: mechanisms of catalysis and inhibition. J Biol Chem 1999;274:22903-6
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8
   PubMed Web of Science ®Google Scholar
• Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-91
   PubMed Web of Science ®Google Scholar
• Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102
   PubMed Web of Science ®Google Scholar
• Dixon DA, Kaplan CD, Mcintyre TM, et al. Post-transcriptional control of cyclooxygenase-2 gene expression: the role of the 3-untranslated region. J Biol Chem 2000;275:11750-7
   PubMed Web of Science ®Google Scholar
• Murphey LJ, Williams MK, Sanchez SC, et al. Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem 2004;334:266-75
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wang M, Yu Y, et al. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest 2006;116:1391-9
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthitis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthitis Safety Study. JAMA 2000;284:1247-55
   PubMed Web of Science ®Google Scholar
• Moreau A, Chen QH, Rao PNP, Knaus EE. Design, synthesis, and biological evaluation of (E)-3-(4-methanesulfonylphenyl)-2-(aryl)acrylic acids as dual inhibitors of cyclooxygenases and lipoxygenases. Bioorg Med Chem 2006;14:7716-27
   PubMed Web of Science ®Google Scholar
• Weir MR, Sperling RS, Reicin A, et al. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J 2003;146:591-604
   PubMed Web of Science ®Google Scholar
• Lu ZH, Xiong X, Zhang BL, et al. Evaluation of 2 celecoxib derivatives: analgesic effect and selectivity to cyclooxygenase-2/11. Acta Pharmacol Sin 2005;26(12):1505-11
   PubMed Web of Science ®Google Scholar
• Navidpour L, Amini M, Shafaroodi H, et al. Design and synthesis of new water-soluble tetrazolide derivatives of celecoxib and rofecoxib as selective cyclooxygenase-2 (COX-2) inhibitors. Bioorg Med Chem Lett 2006;16:4483-7
   PubMed Web of Science ®Google Scholar
• Liu H, Huang XQ, Shen JH, et al. Inhibitory mode of 1,5-diarylpyrazole derivatives against cyclooxygenase-2 and cyclooxygenase-1: molecular docking and 3D QSAR analyses. J Med Chem 2002;45:4816-27
   PubMed Web of Science ®Google Scholar
• Singh SK, Saibaba V, Sprinivasa RK, et al. Synthesis and SAR/3D-QSAR studies on the COX-2 inhibitory activity of 1,5-diarylpyrazoles to validate the modified pharmacophore. Eur J Med Chem 2005;40:977-90
   PubMed Web of Science ®Google Scholar
• Pharmacia Corporation. Stabilized oral pharmaceutical composition. WO02102376; 2002
   Google Scholar
• Pharmacia Corporation. Novel arylsulfonamide prodrugs of COX-2 inhibitors. WO02083655; 2002
   Google Scholar
• Young DV, Cochran ED, Dhawan V, et al. A comparison of the cyclooxygenase inhibitor-NO donors (CINOD), NMI-1182 and AZD3582, using in vitro biochemical and pharmacological methods. Biochem Pharm 2005;70:1343-51
   Google Scholar
• NitroMed, Inc. Novel substituted benzene compounds as COX-2 inhibitors useful for the treatment of gastrointestinal disorders, inflammation, pain, fever and neoplasia. WO04010945; 2004
   Google Scholar
• NitroMed, Inc. Novel oxime- and/or hydrazone-containing nitrosated and/or nitrosylated selective COX-2 inhibitors, useful for the treatment of inflammation. WO04002420; 2004
   Google Scholar
• NitroMed, Inc. Novel nitrosated or nitrosylated 3-phenylpyrazole derivatives with COX-2-inhib-iting and NO-donating activities, useful for the treatment of inflammation. WO04002409; 2004
   Google Scholar
• Ranatunge RR, Augustyniak M, Bandarage UK, et al. Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles. J Med Chem 2004;47:2180-93
   PubMed Web of Science ®Google Scholar
• Merck Frosst Canada & Co. New nitric oxide releasing compounds are selective cyclooxygenase 2 inhibitors - useful for the treatment of inflammatory disease. WO04037798; 2004
   Google Scholar
• Whitehead AJ, Ward RA, Jones MF. Efficient synthesis of the selective COX-2 inhibitor GW406381X. Tetrahedron Lett 2007;48:911-3
   Google Scholar
• Bingham S, Beswick PJ, Bountra C, et al. The cyclooxygenase-2 inhibitor GW406381X [2-(4-Ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-pyrazolo [1,5-b]pyridazine] is effective in animal models of neuropathic pain and central sensitization. J Pharmacol Exp Ther 2005;312:1161-9
   PubMed Web of Science ®Google Scholar
• CJ Corp. Novel bipyridinyl derivatives useful as selective COX-2 inhibitors. WO03055874; 2003
   Google Scholar
• CJ Corp. Novel diaryl 1,2,4-triazole derivatives useful as selective COX-2 inhibitors. WO03055875; 2003
   Google Scholar
• CJ Corp. Use of 1,2,4-triazole derivatives as COX-2 inhibitors - for the prevention and treatment e.g. of fever, pain, inflammation, gastric ulcers and rheumatoid arthritis. WO04048347; 2004
   Google Scholar
• CJ Corp. Novel COX-2-inhibiting 1,2,4-triazole derivatives useful for the treatment of fever, pain, inflammation, cancer and dementia. WO04014878; 2004
   Google Scholar
• CJ Corp. New 1-(3-fluoro-4-methylsulfonyl-phenyl)-5-aryl-3-trifluoromethyl-1,2,4-triazole derivatives are selective COX-2 inhibitors - useful for the treatment of fever, pain, inflammation, cancer and dementia. WO04046121; 2004
   Google Scholar
• Navidpour L, Shafaroodi H, Abdi K, et al. Design, synthesis, and biological evaluation of substituted 3-alkylthio-4, 5-diaryl-4H-1,2,4-triazoles as selective COX-2 inhibitors. Bioorg Med Chem 2006;14:2507-17
   PubMed Web of Science ®Google Scholar
• CJ Corp. 1H-indoles as a highly selective cyclooxygenase-2 inhibitors. WO03031409; 2003
   Google Scholar
• NitroMed, Inc. New 2-methylindole derivatives are selective COX-2 inhibitors – useful for the treatment of inflammation, pain, fever, gastrointestinal disorders, wound healing and diseases resulting from elevated levels of COX-2. WO06099416; 2006
   Google Scholar
• Sedgwick D, Lees P. Studies of eicosanoid production in the air pouch model of synovial inflammation. Agents Actions 1986;18:429-38
   Google Scholar
• Masferrer JL, Zweifel BS, Manning PT, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. PNAS USA 1994;91:3228-32
   PubMed Web of Science ®Google Scholar
• University of Liege. Pyridinic sulfonamide derivatives, method of production and use thereof. WO03029217; 2003
   Google Scholar
• Orchid Research Laboratories Ltd. New pyrimidine carboxamides are TNF-α inhibitors – useful for the treatment of eg pain, inflammation, rheumatoid arthritis, osteoporosis, leukemia, atherosclerosis and cancer. WO07031829; 2007
   Google Scholar
• CJ Corp. 3,4-dihydro-1H-naphthalene derivatives as a highly selective cyclooxygenase-2 inhibitor. WO03031418; 2003
   Google Scholar
• Pharmacia & Upjohn Co. New benzopyran carboxylate derivatives are COX-2 inhibitors - useful for the treatment of inflammation and other conditions. WO06040676; 2006
   Google Scholar
• GD Searle & Co. Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders. US50010050; 2005
   Google Scholar
• Carter J, Brown D, Xing L, Aston K, et al. Benzopyran compounds for use in the treatment and prevention of inflammation related conditions. US50148627; 2005
   Google Scholar
• CJ Corp. 4′-methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor. WO03031398; 2003
   Google Scholar
• CJ Corp. New thione derivatives are cyclooxygenase-2 inhibitors – useful for the treatment of fever, pain and inflammation. WO05051941; 2005
   Google Scholar
• Universita di Bari. New 3, 4-bis-arylisoxazole derivatives are cyclooxygenase inhibitors – useful for the treatment of pain, infllammation and cancer. WO05068442; 2005
   Google Scholar
• Di Nunno L, Vitale P, Scilimati A, et al. Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal. J Med Chem 2004;47:4881-91
   Google Scholar
• Gedeon Richter Ltd. New N-hydroxy-4-(3-phenyl-5-methyl-isoxazole-4-yl)-benzenesulfonamide solvates are COX-2 inhibitors - useful for the treatment of arthritis and pain. WO05007620; 2005
   Google Scholar
• Toyokuni T, Dillep KJS, Walsh JC, et al. Synthesis of 4-(5-[18F]fluoromethyl-3-phenylisoxazol-4-yl)-benzenesulfonamide, a new [18]F]fluorinated analogue of valdecoxib, as a potential radiotracer for imaging cyclooxygenase-2 with positron emission tomography. Bioorg Med Chem Lett 2005;15:4699-702
   Google Scholar
• Biava M, Porretta GC, Poce G, et al. Synthesis, in vitro, and in vivo biological evaluation and molecular docking simulations of chiral alcohol and ether derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents. Bioorg Med Chem 2008;16:8072-81
   PubMed Web of Science ®Google Scholar
• Anzini M, Rovini M, Cappelli A, et al. Synthesis, biological evaluation, and enzyme docking simulations of 1,5-diarylpyrrole-3-alkoxyethyl ethers as selective cyclooxygenase-2 inhibitors endowed with anti-inflammatory and antinociceptive activity. J Med Chem 2008;51:4476-81
   Google Scholar
• Swinney DC, Mak AY, Barnett J, Ramesha CS. Differential allosteric regulation of prostaglandin H synthase-1 and -2 by arachidonic acid. J. Biol. Chem 1997;272:12393-8
   Google Scholar
• Merck Frosst Canada & Co. Synthesis of 4-[(5-substituted or unsubstituted phenyl)-3-substituted-1H-pyrazol -1-yl]benzenesulfonamides. WO00042021; 2000
   Google Scholar
• Generics (UK) Ltd. Novel crystalline adducts of celecoxib with organic solvents, providing improved handling properties. WO03091221; 2003
   Google Scholar
• Generics (UK) Ltd. Novel crystalline forms of celecoxib and other compounds. WO03090730; 2003
   Google Scholar
• Hetero Drugs Ltd. New crystalline form of celecoxib DMF solvate - comprising an N,N-dimethylformamide content of about 4–12% of the weight of the celecoxib DMF solvate. WO05014546; 2005
   Google Scholar
• Pharmacia & Upjohn Co. Crystalline Form IV of celecoxib - useful for the treatment of pain and inflammation. WO06079923; 2006
   Google Scholar
• Pharmacia Corporation. Novel crystalline form of parecoxib sodium useful for treating inflammation, pain, fever and arthritis. WO03078408; 2003
   Google Scholar
• Pharmacia Corporation. Oral dosage form of a sulfonamide prodrug such as parecoxib. WO03041705; 2003
   Google Scholar
• Pharmacia Corporation. New metal salts of parecoxib are prodrugs of valdecoxib – useful for treating inflammation, fever and pain. WO05065684; 2005
   Google Scholar
• Pharmacia Corporation. Transdermal formulations of COX-2 inhibitors. WO02096435; 2002
   Google Scholar
• St John MAR, Abemayor E, Wong DTW. Recent new approaches to the treatment of head and neck cancer. Anti Cancer Drugs 2006;17(4):365-75
   PubMed Web of Science ®Google Scholar
• Sooriakumaran P, Langley SEM, Laing RW. COX-2 inhibition: a possible role in the management of prostate cancer? J Chemotherapy 2007;19(1):21-32
   PubMed Web of Science ®Google Scholar
• Gonzalez-Periz A, Claria J. New approaches to the modulation of the cyclooxygenase-2 and 5-lipoxygenase pathways. Curr Topics Med Chem 2007;7(3):297-309
   PubMed Web of Science ®Google Scholar
• Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acid Res 2000;28:235-42
   PubMed Web of Science ®Google Scholar
• Kiefer JR, Pawlitz JL, Moreland KT, et al. Structural insights into the stereochemistry of the cyclooxygenase reaction. Nature 2000;405:97-101
   Google Scholar
• Rowlinson SW, Kiefer JR, Prusakiewicz JJ, et al. A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. J Biol Chem 2003;278(46):45763-9
   PubMed Web of Science ®Google Scholar
• Sakya SM, Cheng HM, DeMello KML, et al. 5-heteroatom-substituted pyrazoles as canine COX-2 inhibitors: part 2. Structure-activity relationship studies of 5-alkylethers and 5-thioethers. Bioorg Med Chem Lett 2006;16(5):1202-6
   PubMed Web of Science ®Google Scholar
• Sakya SM, DeMello KML, Minich ML, et al. 5-Heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part 1: structure–activity relationship studies of 5-alkylamino pyrazoles and discovery of a potent, selective, and orally active analog. Bioorg Med Chem Lett 2006;16(2):288-92
   PubMed Web of Science ®Google Scholar
• Shahapurkar S, Pandya T, Kawathekar N. Quantitative structure activity relationship studies of diaryl furanones as selective COX-2 inhibitors. Eur J Med Chem 2004;39:899-904
   PubMedGoogle Scholar
• Ranatunge RR, Augustyniak M, Bandarage UK. Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles. J Med Chem 2004;47(9):2180-93
   PubMed Web of Science ®Google Scholar
• Ranatunge RR, Garvey DS, Janero DR. Synthesis and selective cyclooxygenase-2 (COX-2) inhibitory activity of a series of novel bicyclic pyrazoles. Bioorg Med Chem 2004;12(6):1357-66
   PubMed Web of Science ®Google Scholar
• Ranatunge RR, Earl RA, Garvey DS. 3-(2-methoxytetrahydrofuran-2-yl) pyrazoles: a novel class of potent, selective cyclooxygenase-2 (COX-2) inhibitors. Bioorg Med Chem Lett 2004;14(24):6049-52
   PubMed Web of Science ®Google Scholar
• Chen QH, Rao PNP, Knaus EE. Design, synthesis, and biological evaluation of N-acetyl-2-carboxybenzenesulfonamides: a novel class of cyclooxygenase-2 (COX-2) inhibitors. Bioorg Med Chem 2005;13:2459-68
   Google Scholar
• Abouzid K, Bekhit SA. Novel anti-inflammatory agents based on pyridazinone scaffold; design, synthesis and in vivo activity. Bioorg Med Chem 2008;16:5547-56
   PubMed Web of Science ®Google Scholar
• Singh P, Mittal A. Current status of COX-2 inhibitors. Mini Rev Med Chem 2008;8:73-90
   PubMed Web of Science ®Google Scholar
• Chowdhury MA, Dong Y, Chen QH. Synthesis and cyclooxygenase inhibitory activities of linear 1-(methanesulfonylphenyl or benzenesulfonamido)-2(pyridyl)acetylene regioisomers. Bioorg Med Chem 2008;16:1948-56
   Google Scholar
• Da Cunha EFF, Albuquerque MG, Antunes OAC. 4D-QSAR models of HOE/BAY-793 analogues as HIV-1 protease inhihitors. QSAR Comb Sci 2005;24(2):240-53
   Google Scholar
• Da Cunha EFF, Ramalho TC, De Alencastro RB. Interactions of 5-deazapteridine derivatives with Mycobacterium tuberculosis and with human dihydrofolate reductases. J Biomol Struct Dyn 2004;22(2):119-30
   PubMed Web of Science ®Google Scholar
• Da Cunha EFF, Martins RCA, Albuquerque MG. LIV-3D-QSAR model for estrogen receptor ligands. J Mol Mod 2004;10(4):297-304
   Web of Science ®Google Scholar
• Da Cunha EFF, Ramanlho TC, Mala ER, De Alencastro RB. The search for new DHFR inhibitors: a review of patents, January 2001 February 2005. Expert Opin Ther Patents 2005;15(8):967-86
   Web of Science ®Google Scholar
• Araujo LF, Soeiro AM, Fernandes JL, Serrano Júnior. Cardiovascular events: a class effect by COX-2 inhibitors. Arq Bras Cardiol 2005;85(3):222-9
   Google Scholar